Journal of pediatric endocrinology & metabolism : JPEM · 2025
Prognostic analysis of persistent disease in medium-to high-risk children and adolescents with differentiated thyroid carcinoma.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liang Huanxin, Chen Jinsi, Wei Zhixiao, Li Junhong
Аннотация
OBJECTIVES: This multicentre retrospective study aimed to characterise progression-free survival (PFS) patterns and identify clinicopathological factors associated with disease progression in childhood and adolescent differentiated thyroid carcinoma (caDTC) patients with intermediate-to high-risk persistent disease.
METHODS: All patients underwent initial treatment comprising total or near-total thyroidectomy, followed by radioiodine therapy and thyroid-stimulating hormone suppression. Univariate analysis using the log-rank test was performed to evaluate prognostic factors associated with PFS in caDTC patients. The median follow-up duration was 56.1 months (range: 15-112 months).
RESULTS: The 1-, 3-, and 5-year PFS rates among intermediate- and high-risk caDTC patients with persistent disease were 82 , 55, and 32 %, respectively. The median PFS in the structural/functional persistent disease (S/FPD) group was significantly shorter than that in the biochemical persistent disease group (21.5 vs. 51.0 months, p<0.001). High-risk American Thyroid Association (ATA) recurrence risk stratification, stimulated thyroglobulin (sTg) levels ≥ 32.9 ng/mL, and S/FPD response to initial radioiodine therapy (RIT) were significantly associated with poor PFS. The optimal sTg cut-off value for predicting S/FPD status was 32.9 ng/mL, with an area under the receiver operating characteristic curve of 0.76. Sensitivity and specificity were 68 and 88 %, respectively.
CONCLUSIONS: Among caDTC patients with intermediate-to high-risk persistent disease, those with high-risk ATA recurrence stratification, sTg levels ≥ 32.9 ng/mL, and S/FPD response to initial RIT might require more aggressive treatment and closer clinical surveillance.
METHODS: All patients underwent initial treatment comprising total or near-total thyroidectomy, followed by radioiodine therapy and thyroid-stimulating hormone suppression. Univariate analysis using the log-rank test was performed to evaluate prognostic factors associated with PFS in caDTC patients. The median follow-up duration was 56.1 months (range: 15-112 months).
RESULTS: The 1-, 3-, and 5-year PFS rates among intermediate- and high-risk caDTC patients with persistent disease were 82 , 55, and 32 %, respectively. The median PFS in the structural/functional persistent disease (S/FPD) group was significantly shorter than that in the biochemical persistent disease group (21.5 vs. 51.0 months, p<0.001). High-risk American Thyroid Association (ATA) recurrence risk stratification, stimulated thyroglobulin (sTg) levels ≥ 32.9 ng/mL, and S/FPD response to initial radioiodine therapy (RIT) were significantly associated with poor PFS. The optimal sTg cut-off value for predicting S/FPD status was 32.9 ng/mL, with an area under the receiver operating characteristic curve of 0.76. Sensitivity and specificity were 68 and 88 %, respectively.
CONCLUSIONS: Among caDTC patients with intermediate-to high-risk persistent disease, those with high-risk ATA recurrence stratification, sTg levels ≥ 32.9 ng/mL, and S/FPD response to initial RIT might require more aggressive treatment and closer clinical surveillance.